On Tuesday, H.C. Wainwright adjusted its outlook on Revolution Medicines (NASDAQ:RVMD), raising the 12-month price target to $56 from the previous $44 while maintaining a Buy rating on the stock. This revision follows the recent presentation of Phase 1 trial results by Revolution Medicines for its cancer drug, RMC-6236.
Revolution Medicines' RMC-6236, designed to target KRASG12X mutations in pancreatic cancer, showed encouraging efficacy in the Phase 1 dose escalation study. The study included 127 patients with pancreatic adenocarcinoma who had undergone at least two prior treatments. According to the data, RMC-6236 achieved objective response rates (ORR) of 20% and 27% at the 14+ and 20+ week benchmarks, respectively.
The median progression-free survival (mPFS) was reported at 8.1 months for second-line (2L) treatment and 4.2 months for third-line (3L) treatment. These outcomes were deemed impressive by H.C. Wainwright, as they surpassed the results of historical controls. Furthermore, the safety profile of the drug was considered manageable, with 22% of participants experiencing Grade 3 or higher treatment-related adverse events (TRAEs), and no treatment discontinuations due to TRAEs were reported.
In light of these results, H.C. Wainwright has reduced the projected discount rate for RMC-6236 to 10% from 11% and increased the probability of the drug's approval in second-line or higher pancreatic adenocarcinoma treatment to 60% from the previous estimate of 50%. These adjustments underpin the firm's decision to reiterate its Buy rating and elevate the price target for Revolution Medicines' shares.
In other recent news, Revolution Medicines has seen multiple upgrades in its share price target following promising clinical trial results. JPMorgan (NYSE:JPM) increased its price target for the company to $55, maintaining an Overweight rating, based on new phase 1 results for drug RMC-6236 in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The firm also anticipates an accelerated launch timeline for RMC-6236, now expected in 2028.
Oppenheimer also raised its price target for Revolution to $55, acknowledging the drug's unique mechanism of action and its potential to de-risk the Phase 3 program. BofA Securities increased its price target for Revolution to $55 following a positive clinical trial outcome for RMC-6236, raising the probability of success in their model from 25% to 35%.
Jefferies raised its target to $73 based on improved probability of the drug's success in treating PDAC, while Stifel increased its target to $57 following promising monotherapy results. These recent developments highlight the growing confidence in the potential of Revolution Medicine's RMC-6236.
InvestingPro Insights
In tandem with the optimism from H.C. Wainwright on Revolution Medicines' promising drug trial results, InvestingPro data and tips provide a nuanced view of the company's financial health and stock performance. Revolution Medicines holds a market capitalization of approximately $7.59 billion, reflecting its significant growth potential in the biotech sector. Additionally, the stock has shown a remarkable return over the last year with a 72.54% increase, aligning with the positive trial outcomes and investor confidence.
An InvestingPro Tip worth noting is that Revolution Medicines possesses more cash than debt on its balance sheet, indicating a strong financial position to fund ongoing research and development efforts. Moreover, the company's liquid assets exceed its short-term obligations, further reinforcing its financial stability. On the flip side, analysts have expressed concerns, as highlighted by another InvestingPro Tip, about the company's profitability, not anticipating Revolution Medicines to be profitable this year. This is corroborated by the substantial negative gross profit margin reported over the last twelve months, as of Q1 2024.
For investors seeking a more in-depth analysis, InvestingPro offers additional tips that provide valuable insights into Revolution Medicines' stock performance and financial metrics. Readers can use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking further exclusive tips and data to inform their investment decisions. Currently, there are 12 additional InvestingPro Tips available, which may help investors gauge the short-term and long-term potential of their investment in Revolution Medicines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.